AVITA Medical, Inc. (RCEL) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. AVITA Medical is a therapeutic acute wound care company focused on the RECELL System (autologous skin cell suspension), PermeaDerm, and Cohealyx. The company operates as a single reporting segment with a primary focus on U.S. burn and trauma centers. As of the filing date, the company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $17.1 million | $19.5 million | $54.0 million | $45.8 million |
| Gross Profit | $13.9 million | $16.4 million | $44.5 million | $39.0 million |
| Gross Margin | 81.3% | 83.7% | 82.4% | 85.1% |
| Operating Loss | $(9.2) million | $(13.8) million | $(32.1) million | $(46.6) million |
| Net Loss | $(13.2) million | $(16.2) million | $(37.0) million | $(50.3) million |
| Cash & Equivalents | $15.4 million | $18.6 million (Sep 2024) | Marketable Securities: $7.9 million (Sep 2025) | |
| Total Debt (Loan Facility) | $42.4 million (Current) | $42.2 million (Long-term) |
Liquidity: As of September 30, 2025, the company held $15.4 million in cash and cash equivalents and $7.9 million in marketable securities. The company raised $14.8 million in gross proceeds via a private placement on the ASX in August 2025.
Material Changes vs. Prior Period
- Revenue: Q3 2025 revenue decreased 13% year-over-year to $17.1 million, primarily due to Medicare Administrative Contractor (MAC) reimbursement headwinds. However, YTD revenue increased 18% to $54.0 million, driven by deeper customer penetration and new product launches (Cohealyx, RECELL GO mini).
- Expenses: Total operating expenses decreased 24% in Q3 and 11% YTD compared to the prior year, reflecting cost-saving initiatives including sales force reductions and lower stock-based compensation.
- Debt Classification: The entire $42.4 million loan facility is now classified as a current liability due to substantial doubt regarding the company's ability to maintain the minimum cash balance covenant within the next 12 months.
- Other Income/Expense: Q3 included a $2.2 million non-cash charge related to the issuance of common stock for a debt amendment and a $0.9 million charge for the change in fair value of the loan facility.
Outlook, Risks, and Management Commentary
- Going Concern: Management has determined that, absent mitigating action, the company may not be able to maintain compliance with the minimum cash balance covenant in its Credit Agreement within the next 12 months. This raises substantial doubt about the company's ability to continue as a going concern.
- Debt Covenants: The company has received multiple waivers for trailing 12-month net revenue covenants for Q1, Q2, and Q3 2025. A sixth amendment in November 2025 adjusted the Q4 2025 revenue covenant to $70.0 million and added $500,000 to the principal balance.
- Recent Developments:
- CMS NTAP: On October 1, 2025, CMS approved a New Technology Add-On Payment (NTAP) for the RECELL System for acute non-thermal full-thickness skin defects, allowing up to $4,875 additional reimbursement per case.
- CE Mark: RECELL GO obtained CE Mark approval in September 2025, enabling commercialization in the EU.
- Leadership Change: James Corbett departed as CEO and Director effective October 16, 2025. Cary Vance was appointed Interim CEO.
- Strategic Focus: The company is pausing investment in vitiligo due to reimbursement challenges and is focusing on U.S. burn/trauma centers and the commercialization of Cohealyx and PermeaDerm.
Investor Verification Checklist
- Covenant Compliance: Verify the company's ability to meet the revised Q4 2025 revenue covenant of $70.0 million and the minimum cash balance requirement to avoid debt acceleration.
- Capital Needs: Assess the timeline and likelihood of securing additional equity or debt financing given the "going concern" warning and current cash burn rate.
- Reimbursement Impact: Monitor the actual uptake of the new CMS NTAP reimbursement code and its effect on Q4 2025 and 2026 revenue recovery.
- Leadership Transition: Evaluate the stability of operations and strategic execution under the new Interim CEO, Cary Vance.
- Contingent Liabilities: Review the $3.0 million contingent liability related to the Regenity Agreement, which is due by January 4, 2026, contingent on clinical study results.